Glucose-responsive hydrogels find more extensive application in diabetic disease management compared to cancer therapy, primarily due to the higher prevalence of diabetes and the urgent need for precise insulin delivery in diabetic patients. This evidence concerns the gene INS and diabetes mellitus.